References of "MAGIS, Delphine"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailNeurostimulation for Headaches: Where Are We? Where Are We Going?
MAGIS, Delphine ULg

in May, Arne; Baron, Ralf (Eds.) Headache and Pain (2014)

Detailed reference viewed: 15 (0 ULg)
Full Text
Peer Reviewed
See detailSafety and patients' satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly® device in headache treatment: a survey of 2,313 headache sufferers in the general population.
MAGIS, Delphine ULg; SAVA, Simona Liliana ULg; D'Elia, Tullia Sasso et al

in Journal of Headache & Pain (2013), 14

BACKGROUND: Transcutaneous supraorbital nerve stimulation (tSNS) with the Cefaly® device was recently found superior to sham stimulation for episodic migraine prevention in a randomized trial. Its safety ... [more ▼]

BACKGROUND: Transcutaneous supraorbital nerve stimulation (tSNS) with the Cefaly® device was recently found superior to sham stimulation for episodic migraine prevention in a randomized trial. Its safety and efficiency in larger cohorts of headache sufferers in the general population remain to be determined.The objective of this study was to assess the satisfaction with the Cefaly® device in 2,313 headache sufferers who rented the device for a 40-day trial period via Internet. METHODS: Only subjects using specific anti-migraine drugs, and thus most likely suffering from migraine, were included in the survey. Adverse events (AEs) and willingness to continue tSNS were monitored via phone interviews after the trial period. A built-in software allowed monitoring the total duration of use and hence compliance in subjects who returned the device to the manufacturer after the trial period. RESULTS: After a testing period of 58.2 days on average, 46.6% of the 2,313 renters were not satisfied and returned the device, but the compliance check showed that they used it only for 48.6% of the recommended time. The remaining 54.4% of subjects were satisfied with the tSNS treatment and willing to purchase the device. Ninety-nine subjects out of the 2,313 (4.3%) reported one or more AEs, but none of them was serious. The most frequent AEs were local pain/intolerance to paresthesia (47 subjects, i.e. 2.03%), arousal changes (mostly sleepiness/fatigue, sometimes insomnia, 19 subjects, i.e. 0.82%), headache after the stimulation (12 subjects, i.e. 0.52%). A transient local skin allergy was seen in 2 subjects, i.e. 0.09%. CONCLUSIONS: This survey of 2,313 headache sufferers in the general population confirms that tSNS with is a safe and well-tolerated treatment for migraine headaches that provides satisfaction to a majority of patients who tested it for 40 days. Only 4.3% of subjects reported AEs, all of them were minor and fully reversible. [less ▲]

Detailed reference viewed: 7 (0 ULg)
Full Text
Peer Reviewed
See detailNeuromodulation of chronic headaches: position statement from the European Headache Federation
Martelletti, P; Jensen, R; Antal, A et al

in Journal of Headache & Pain (2013), 14

The medical treatment of patients with chronic primary headache syndromes (chronic migraine, chronic tension-type headache, chronic cluster headache, hemicrania continua) is challenging as serious side ... [more ▼]

The medical treatment of patients with chronic primary headache syndromes (chronic migraine, chronic tension-type headache, chronic cluster headache, hemicrania continua) is challenging as serious side effects frequently complicate the course of medical treatment and some patients may be even medically intractable. When a definitive lack of responsiveness to conservative treatments is ascertained and medication overuse headache is excluded, neuromodulation options can be considered in selected cases.Here, the various invasive and non-invasive approaches, such as hypothalamic deep brain stimulation, occipital nerve stimulation, stimulation of sphenopalatine ganglion, cervical spinal cord stimulation, vagus nerve stimulation, transcranial direct current stimulation, repetitive transcranial magnetic stimulation, and transcutaneous electrical nerve stimulation are extensively published although proper RCT-based evidence is limited. The European Headache Federation herewith provides a consensus statement on the clinical use of neuromodulation in headache, based on theoretical background, clinical data, and side effect of each method. This international consensus further gives recommendations for future studies on these new approaches.In spite of a growing field of stimulation devices in headaches treatment, further controlled studies to validate, strengthen and disseminate the use of neurostimulation are clearly warranted. Consequently, until these data are available any neurostimulation device should only be used in patients with medically intractable syndromes from tertiary headache centers either as part of a valid study or have shown to be effective in such controlled studies with an acceptable side effect profile. [less ▲]

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailPearls and pitfalls: Electrophysiology for primary headaches
MAGIS, Delphine ULg; Vigano, Alessandro; SAVA, Simona Liliana ULg et al

in Cephalalgia : An International Journal of Headache (2013)

Detailed reference viewed: 43 (5 ULg)
See detailPerspectives thérapeutiques dans la migraine
MAGIS, Delphine ULg

Scientific conference (2013, March 22)

Detailed reference viewed: 24 (6 ULg)
Full Text
Peer Reviewed
See detailTranscranial Direct Current Stimulation (tDCS) of the visual cortex: a proof-of-concept study based on interictal electrophysiological abnormalities in migraine
Vigano, Alessandro; Sasso d'Elia, Tullia; SAVA, Simona Liliana ULg et al

in Journal of Headache & Pain (2013), 14(23),

Detailed reference viewed: 55 (4 ULg)
Full Text
Peer Reviewed
See detailLateral inhibition in visual cortex of migraine patients between attacks
Coppola, Gianluca; Parisi, Vincenzo; Di Lorenzo, Cherubino et al

in Journal of Headache & Pain (2013), 14

Detailed reference viewed: 19 (1 ULg)
Full Text
Peer Reviewed
See detailMigraine prevention with a supraorbital transcutaneous stimulator. A randomized controlled trial.
Schoenen, Jean ULg; Vandersmissen, Bart; Jeangette, Sandrine et al

in Neurology (2013), 80

Detailed reference viewed: 91 (3 ULg)
Full Text
Peer Reviewed
See detailScientific advances in headache research: an update on neurostimulation
Hoffmann, Jan; MAGIS, Delphine ULg

in Expert Review of Neurotherapeutics (2013), 13(1), 15-17

Detailed reference viewed: 23 (1 ULg)
Full Text
Peer Reviewed
See detailQuadripulse Repetitive Transcranial Magnetic Stimulation on Visual Cortex for Chronic Migraine Prevention: A Pilot-Trial
Sasso d'Elia, Tullia; Vigano, Alessandro; Fataki, Michel et al

in Cephalalgia : An International Journal of Headache (2013), 33(8), 49

Detailed reference viewed: 14 (1 ULg)
See detailNeurostimulation et céphalées
MAGIS, Delphine ULg

Scientific conference (2012, December 11)

Detailed reference viewed: 8 (3 ULg)
Peer Reviewed
See detailNeurostimulation for headaches
MAGIS, Delphine ULg

Conference (2012, October 07)

Detailed reference viewed: 3 (0 ULg)
Full Text
Peer Reviewed
See detailAnodal transcranial direct current stimulation over the visual cortex as a preventive treatment of migraine: a proof-of-concept study.
Sasso d'Elia, Tullia; Vigano, Alessandro; SAVA, Simona Liliana ULg et al

in Frontiers in Human Neuroscience (2012, September)

Detailed reference viewed: 23 (2 ULg)